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http://www.ro-journal.com/content/9/1/207RESEARCH Open AccessBAY 87–2243, a novel inhibitor of hypoxia-induced
gene activation, improves local tumor control after
fractionated irradiation in a schedule-dependent
manner in head and neck human xenografts
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Background: The transcription factor hypoxia-inducible factor-1 (HIF-1) pathway plays an important role in tumor
response to cytotoxic treatments. We investigated the effects of a novel small molecule inhibitor of mitochondrial
complex I and hypoxia-induced HIF-1 activity BAY-87-2243, on tumor microenvironment and response of human
squamous cell carcinoma (hSCC) to clinically relevant fractionated radiotherapy (RT) with and without concomitant
chemotherapy.
Methods: When UT-SCC-5 hSCC xenografts in nude mice reached 6 mm in diameter BAY-87-2243 or carrier was
administered before and/or during RT or radiochemotherapy with concomitant cisplatin (RCT). Local tumor control
was evaluated 150 days after irradiation and the doses to control 50% of tumors (TCD50) were compared between
treatment arms. Tumors were excised at different time points during BAY-87-2243 or carrier treatment for western
blot and immunohistological investigations.
Results: BAY-87-2243 markedly decreased nuclear HIF-1α expression and pimonidazole hypoxic fraction already after
3 days of drug treatment. BAY-87-2243 prior to RT significantly reduced TCD50 from 123 to 100 Gy (p=0.037). Additional
BAY-87-2243 application during RT did not decrease TCD50. BAY-87-2243 before and during radiochemotherapy did
not improve local tumor control.
Conclusions: Pronounced reduction of tumor hypoxia by application of BAY-87-2243 prior to RT improved local tumor
control. The results demonstrate that radiosensitizing effect importantly depends on treatment schedule. The data
support further investigations of HIF-1 pathway inhibitors for radiotherapy and of predictive tests to select patients who
will benefit from this combined treatment.
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Many solid tumors express hypoxia-inducible factor-1α
(HIF-1α), which is associated with poor prognosis after
surgery, radiotherapy, and chemotherapy in several can-
cer types [1-5]. Tumor hypoxia, among other stress
conditions [6-8], is recognized as a major regulator of
multiple HIF-1-mediated pathways which promote cell
survival [9]. Hypoxia leads to the stabilization and accu-
mulation of HIF-1α protein, which translocates to the
nucleus and forms a heterodimer with its partner HIF-1β.
This transcriptional complex induces the transcription of
numerous genes with adaptive functions, e.g. vascular
endothelial growth factor and glucose transporter 1 to in-
crease oxygen availability and to allow metabolic adapta-
tion to oxygen deprivation.
Pharmacological or genetic targeting of HIF-1 sensi-
tized tumor cells to radiation and chemotherapeutic
DNA damaging agents and decreased tumor growth
[10-15]. Beside direct radiosensitization of tumor cells
caused by HIF-1 inhibition other mechanisms such as
radiosensitization of tumor vasculature or reduction of
tumor hypoxia have been shown to contribute to the en-
hanced effect of radiation therapy [16-19]. Resistance of
hypoxic tumor cells to chemotherapy was attributed to
several factors including poor drug distribution, reduced
drug uptake, activation of genes leading to a drug-resistant
phenotype [20]. Recent studies have demonstrated an im-
portant role of HIF-1 in resistance to chemotherapeutic
agents such as platinum-containing anti-cancer drugs, e.g.
through regulation of XPA (xeroderma pigmentosum
group A) protein that senses DNA damage and recruits
other DNA repair proteins to the damaged template in the
nucleotide excision repair pathway [21,22].
BAY-87-2243 inhibits mitochondrial production of re-
active oxygen species (ROS) by blocking mitochondrial
complex I, which subsequently reduces hypoxia-induced
HIF-1 activity [23]. Being encouraged by our recent find-
ings using the compound BAY-84-7296 with the same
mode of action but lower on-target efficiency as its de-
rivative BAY-87-2243, which completely resolved tumor
hypoxia and pronouncedly increased local tumor control
after irradiation with large single doses in two different
hSCCs of head and neck, UT-SCC-14 and UT-SCC-5,
in vivo [24], we tested in the present study whether
BAY-87-2243 leads to the reduction of tumor hypoxia
and improves the outcome of clinically relevant fraction-
ated irradiation with and without concomitant cisplatin
treatment. The fractionation protocol with 30 fractions
over 6 weeks was chosen to account for potential inter-
actions between the compound and radiobiological
mechanisms of fractionated irradiation such as repopula-
tion, reoxygenation, recovery and redistribution, which
by design did not contribute to local tumor control after
single dose irradiation. UT-SCC-5 hSCC was chosen forthe experiments because this tumor model is more radio-
resistant and exhibits higher expression of HIF-1α and
hypoxic fraction as compared with UT-SCC-14 [24,25].
The efficacy of various combination regimens have been
tested using a series of TCD50 (dose to cure 50% of tu-
mors) assays in nude mice. We show that radiosensitizing
effect of BAY-87-2243 with fractionated irradiation de-
pends on treatment schedule, which may provide import-
ant information for the design of clinical trials.
Methods
BAY-87-2243, cisplatin
BAY-87-2243 was developed by Bayer Pharma AG. For
the experiments BAY-87-2243 was dissolved in carrier so-
lution (10% ethanol, 40% Solutol® HS15, 50% sterile dis-
tilled water) and administered orally by gavage (9 mg/kg/
body weight [b.w.]). Control animals were treated with the
carrier solution. Cisplatin (Calbiochem, Germany, 3 mg/
kg/b.w.) dissolved in saline (NaCl 0.9%) was administered
intraperitoneally (i.p.).
Animals and tumor model
The experiments were performed using 7 to 14 week-old
male and female NMRI (nu/nu) nude mice obtained
from the pathogen-free animal breeding facility (Experi-
mental Centre, Medical Faculty, TU Dresden, Germany).
Two to five days prior to tumor transplantation the
nude mice received a total body irradiation (4 Gy,
200 kV X-rays, 0.5 mm Cu-filter, ~1 Gy/min) for further
immunosuppression. The experiments and the animal
facilities were approved according to the institutional
guidelines and the German animal welfare regulations.
The experiments were performed using the established
hSCC of the tongue UT-SCC-5 with hypoxia-induced
activation of HIF-1α [26]. Small pieces of a source tumor
were transplanted subcutaneously into the right hind-leg
of anesthetized mice (120 mg/kg b.w. ketamine i.p. and
16 mg/kg xylazine i.p.). The volume doubling time,
histological examinations and DNA-microsatellite profile
confirmed the identity of the transplanted UT-SCC-5
xenografts.
Tumor sampling
BAY-87-2243 or carrier solution were applied once tu-
mors reached 4 mm (~33 mm3) in diameter until the
tumors reached 7 mm (~180 mm3) or once tumors
reached 6 mm for 3, 5, or 7 days. At these time points
the tumors were excised 24 h after the last carrier or
BAY-87-2243 administration (3–9 mice per treatment
group) for immunohistochemistry or western blotting.
Prior to tumor harvesting the hypoxia marker pimonida-
zole (Natural Pharmacia International, Inc., Research
Triangle Park, NC, USA; 0.1 mg/g b.w., dissolved at
10 mg/ml in 0.9% NaCl, i.p.) was injected one hour
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33342 (Sigma Aldrich, Deisenhofen, Germany; 0.75 mg
in PBS, intravenously [i.v.]) one minute before excision.
Half of the tumor was immediately snap frozen in liquid
nitrogen and stored at −80°C. The second half was fixed
overnight in 4% formalin and embedded in paraffin.
Tumor growth delay and TCD50 assay
In tumor growth delay assay randomized mice were
treated daily with carrier (n=39) or BAY-87-2243 (n=41)
when tumors reached a size of 4 mm in diameter until
the tumors grew to 7 mm in diameter. Time to reach
7 mm was compared between treatment groups.
In TCD50 assay six experimental treatments were tested
combining fractionated radiotherapy (RT) or cisplatin
based radiochemotherapy (RCT) with BAY-87-2243:
1) RT: 30 fractions delivered over 6 weeks. Carrier was
applied before and during radiotherapy.
2) BAY-87-2243 + RT: pre-treatment with BAY-87-2243
followed by RT with carrier.
3) BAY-87-2243 + RT/BAY-87-2243: treatment with
BAY-87-2243 before and during RT.
4) RCT: 30 fractions over 6 weeks combined with
cisplatin once per week after irradiation. Carrier was
applied before and during RCT.
5) RCT/BAY-87-2243: pre-treatment with carrier
followed by RCT with BAY-87-2243.
6) BAY-87-2243 + RCT/BAY-87-2243: treatment with
BAY-87-2243 before and during RCT.
Pre-treatment with carrier or BAY-87-2243 was always
performed on three consecutive days followed by RT
24 h after the last application. Carrier or BAY-87-2243
was administered after each radiation fraction during
radiotherapy.
Treatments started when tumor size reached 6 mm in
diameter. Animals were randomly allocated in six groups
with total doses between 60 Gy and 160 Gy (5–12 mice
per dose group) delivered in 30 equal fractions (dose per
fraction between 2 and 5.3 Gy). All irradiations were
performed under normal blood flow conditions without
anaesthesia. During irradiation animals were immobi-
lized using plastic tubes fixed on a lucite plate and the
tumor-bearing leg was positioned in the irradiation field
by a foot holder distal to the tumor. The tumor diame-
ters were measured using a caliper twice per week and
once per week 90 days after irradiation. Tumor volume
was calculated by π/6 ⋅ a ⋅ b2, where a is the longest and
b is the perpendicular shorter tumor diameter. When
tumor volume increased for three consecutive measure-
ments after shrinkage or when tumors continued to
grow without shrinkage they were scored as recurrence.
The animals were sacrificed when the recurrent tumorreached the diameter of 15 mm or when the animal ap-
peared to suffer. A total of 343 mice were observed after
treatment for a maximum time of 150 days, which is suf-
ficient to detect all local failures in UT-SCC-5 [26].
Ninety five percent of 200 local failure events occurred
before day 69 and the latest recurrence was scored at
day 150. A total of 71 mice censored between 21 and
149 days were included in the analysis [25]. Fitting of
the local control data, calculation of the TCD50 values,
of 95% confidence intervals for TCD50 and of p-values
for comparisons of treatment groups were performed as
described previously [25]. Enhancement ratio (ER) was
calculated as the ratio between the TCD50 value of the
control group and the TCD50 of the experimental group.
Western blot analysis of HIF-1α
Western blotting was performed one time according to
the established protocol as described previously [24].
Protein samples were prepared using the NE-PER Nuclear
and Cytoplasmic KIT (Thermo Scientific, Germany) ac-
cording to the manufacturer’s instructions. Antibodies
used were mouse monoclonal anti-human HIF-1α (1:250,
BD Biosciences, USA) and rabbit polyclonal anti-histone-
H2B (1:500, Imgenex, USA) and anti-Calpain 1 (1:1000,
Cell Signaling, USA) served as the loading controls for
nuclear or cytoplasmic cell compartments, respectively.
Nuclear HIF-1α band intensities were normalized to
histone-H2B levels.
Histological studies
Two 10 μm frozen cross-sections from tumor centre
were stained for pimonidazole (rabbit anti-pimonidazole
antisera, Burlington, USA) and CD31 (rat anti-mouse
CD31, clone MEC 13.3, PharMingen/BD Biosciences,
Heidelberg, Germany), scanned and blindly analysed as
described in detail previously [26]. After scanning, the
same tumor sections were stained with haematoxylin
and eosin for identification of viable and necrotic
tumour subareas by morphological criteria. The pimoni-
dazole hypoxic fraction (pHF) and the relative vascular
area (RVA) were calculated as the percentage of the vi-
able tumor area stained for pimonidazole or CD31, re-
spectively. The fraction of perfused vessels (PF) was
calculated as the percentage of the vascular area over-
lapped with Hoechst 33342 perfusion marker. Necrotic
fraction (NF) was determined as the necrotic tumor area
divided by the total tumor area. The immunohistochem-
istry staining protocol for HIF-1α (mouse monoclonal
anti-human HIF-1α, BD Biosciences, USA) has previ-
ously been described in detail [24,27].
Statistical analysis
Normality of distributions was tested using the skewness
and kurtosis test. Mean values were compared using the
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test was used to compare non-normal distributions.
P-values were adjusted for multiple comparisons using
the Scheffe correction when relevant. Statistical analysis
was performed using a commercial software package
STATA/SE 8.0 (STATA Corporation, College Station, TX,
USA). P-values less or equal to 0.05 were considered as
statistically significant.
Results
To test the inhibitory effect of BAY-87-2243 on HIF-1α
protein expression, tumors were treated with the drug
for 3, 5 or 7 consecutive days. Nuclear HIF-1α protein
levels were strongly suppressed after 3 days of drug
treatment (Figure 1). Cytoplasmic cell extracts showed
none or very weak HIF-1α protein expression (data not
shown). To study the kinetics of changes in tumor
microenvironment induced by BAY-87-2243, hypoxia,
vasculature and perfused vessels were examined in tu-
mors after 3, 5 and 7 days of drug treatment. Three daily
applications of BAY-87-2243 markedly reduced pHF to























Figure 1 BAY-87-2243 inhibits nuclear HIF-1α protein expression. UT-
or 7 days and were excised 24 h after end of treatment: a) immunohistoch
bar: 20 μm; b) western blots of nuclear HIF-1α from different animals 3 day
densitometry relative to histone-H2B, means ± SD.0.0001, Figures 2 and 3a). This decrease in pHF re-
mained after BAY-87-2243 treatment for 5 and 7 days. A
statistically significant reduction in RVA was found 5
and 7 days after BAY-87-2243 treatment as compared
with carrier-treated tumors (p=0.033 and p=0.026, re-
spectively, Figure 3a). BAY-87-2243 did not affect PF at
any time point. Necrotic fraction was statistically signifi-
cantly lower only after 3 days of drug treatment (p=0.018).
Anti-tumor effects of BAY-87-2243 were tested using
daily application from 4 mm tumor diameter to 7 mm.
BAY-87-2243 alone significantly inhibited the growth of
UT-SCC-5 tumors. The median time to reach 7 mm
tumor diameter was 18 days for BAY-87-2243 as com-
pared with 11 days for carrier treated tumors (p < 0.0001,
Figure 3b). Administration of BAY-87-2243 for about
18 days significantly reduced HIF-1α protein expression
(data not shown) as well as pHF (mean 2.4% (BAY-87-
2243) vs. 17.6% (carrier), p < 0.0001), and NF (mean 9%
vs. 35.6%, p=0.0002), whereas RVA and PF remained
unchanged.
To test whether BAY-87-2243 improves local tumor

























SCC-5 tumors were treated either with BAY-87-2243 or carrier for 3, 5,
emistry, black arrows indicate the positive nuclear HIF-1α staining, scale
s after BAY-87-2243 application; c) quantification of western blots by
Figure 2 Pseudo-coloured images of cross-sections from tumors excised 24 h after end of treatment with BAY-87-2243 or carrier for 3, 5 or
7 days. Green: hypoxia, pimonidazole; blue: perfusion, Hoechst 33342; red: vascular endothelium, CD31; grey: necrotic areas. Scale bar: 500 μm.























































































Figure 3 Effects of BAY-87-2243 on tumor microenvironment and tumor growth. a) Pimonidazole hypoxic fraction (pHF), relative vascular
area (RVA), fraction of perfused vessels (PF), and necrotic fraction (NF) in UT-SCC-5 tumors 24 h after end of treatment with BAY-87-2243 or carrier
for 3, 5, or 7 days (n=7-9 tumors per time point and treatment group). b) Time to grow from 4 to 7 mm tumor diameter. UT-SCC-5 tumors were
treated daily with BAY-87-2243 or carrier. Bars represent means ± SD of histological parameters or medians ± MAD (median absolute deviation) of
growth times. Asterisks indicate significant differences from carrier control.
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either halted before irradiation with 30 fractions within
6 weeks or was continued during irradiation. Whereas
pre-treatment with BAY-87-2243 for 3 days prior to
irradiation (BAY-87-2243 + RT) significantly reduced
TCD50, the decrease in TCD50 after concomitant BAY-
87-2243 treatment during irradiation (BAY-87-2243 +
RT/BAY-87-2243) was less pronounced and statistically
not significant (Table 1, Figure 4a). The enhancement
ratio greater than 1 indicates that the dose to achieve
the same local control rate (i.e. TCD50) is reduced by
BAY-87-2243 in comparison with radiation alone. To
test whether BAY-87-2243 decreases TCD50 after frac-
tionated radiochemotherapy (RCT) BAY-87-2243 was
combined with cisplatin and irradiation with 30 fractions
within 6 weeks. The TCD50 after RCT was lower by a
factor of 1.23 in comparison with RT alone. This effect
was only marginally significant (p=0.09) likely due to
considerable intertumoral heterogeneity in response to
RCT as suggested by shallow dose–response curve
(Figure 4b). Local tumor control was not significantly
improved if BAY-87-2243 was administered during frac-
tionated irradiation combined with weekly administra-
tion of cisplatin (RCT/BAY-87-2243). Pre-treatment
with BAY-87-2243 for 3 days in addition to continuous
BAY-87-2243 application during RCT (BAY-87-2243 +
RCT/BAY-87-2243) also did not result in reduction of
TCD50 (Table 1, Figure 4b).
Discussion
To our knowledge this experimental study demonstrates
for the first time that BAY-87-2243, an inhibitor of
hypoxia-induced gene activation, improves local tumor
control after clinically relevant fractionated irradiation.
The novelty of our findings is given by the fact that hereTable 1 Summary of TCD50 values and enhancement ratios
(ER) for different treatments
Experimental arm TCD50 [95% CI] (Gy)
(p-value vs. control)
ER
1) RT 122.7 [108;149]
-
-
2) BAY-87-2243 + RT 99.7 [88;117]
(0.037)
1.23
3) BAY-87-2243 + RT/BAY-87-2243 114.3 [103;132]
(0.4)
1.07
4) RCT 99.5 [83;124]
-
-
5) RCT/BAY-87-2243 107.2 [97;123]
(0.5)
0.93
6) BAY-87-2243 + RCT/BAY-87-2243 113.6 [97; 145]
(0.3)
0.88
P-value <0.05 indicates significant differences between experimental treatment
and respective control (RT or RCT).we used fractionated irradiation which, in contrast to
single dose irradiation used in our previous experiment
[24], allows for specific scheduling evaluation and poten-
tial interaction with radiobiological mechanisms relevant
to local tumor control after fractionated irradiation such
as reoxygenation, repopulation, recovery and redistribu-
tion. The radiosensitizing effect was schedule-dependent
and only significant if BAY-87-2243 was administered
prior to fractionated irradiation. In contrast, concomi-
tant administration of BAY-87-2243 during fractionated
irradiation with or without cisplatin did not improve
local tumor control. Whether pre-treatment with BAY-
87-2243 before start of radiochemotherapy affects local
tumor control was not tested in the present experiments
and remains to be elucidated. Thus, our data do not
allow to assess whether the efficacy of BAY-87-2243 be-
fore initiation of fractionated radiotherapy depends on
whether this is given alone or in combination with
chemotherapy. When the experiments were designed we
hypothesized based on our previous data [24] and find-
ings by others that experimental arms 3 (BAY-87-2243 +
RT/BAY-87-2243) and 6 (BAY-87-2243 + RCT/BAY-87-
2243) are the most effective ones. However, unexpect-
edly concomitant BAY-87-2243 was not effective or even
reversed the effect of pre-RT drug administration. Taken
together, our data indicate a schedule dependence of the
radiosensitizing effect of BAY-87-2243 but further exper-
iments are necessary to confirm this conclusion.
The present data and our previous findings [24] sug-
gest that the reduction in tumor hypoxia represents the
underlying radiosensitizing mechanism of BAY-87-2243.
Although we did not specifically investigate the mecha-
nisms of reoxygenation induced by BAY-87-2243, the
observed rapid drop in hypoxia already after 3 days of
treatment with unchanged tumor vascular area and per-
fused functional vessels may suggest a cytotoxic effect of
BAY-87-2243 on hypoxic tumor cells, e.g. blockage of
HIF-1-mediated hypoxia tolerance [28]. However, nec-
rotic fraction initially decreased and later remained un-
changed in BAY-87-2243 treated tumors, it remains
unclear to what extent rapid resorption of necrotic cells
and/or reduction of proliferation and thereby oxygen
consumption may have contributed to this observation.
Normalisation of the microvasculature appears less likely
to explain the reduction in hypoxia as longer treatments
with BAY-87-2243 for 5 and 7 days resulted in a de-
crease of vascular area and unchanged perfused vessels.
Reduction in tumor vascularization upon HIF-1 inhib-
ition has been also demonstrated by others, which was
associated with the decreased gene expression of angio-
genic growth factors and decreased mobilization of cir-
culating angiogenic cells [29]. In the latter study these
effects on tumor vasculature contributed to the reduced
growth of tumor xenografts similarly to our findings.




































Figure 4 Effect of BAY-87-2243 on local tumor control. Dose-response curves after a) BAY-87-2243 combined with radiotherapy with 30 fractions
within 6 weeks (RT) and b) BAY-87-2243 combined with fractionated radiochemotherapy with cisplatin (RCT). Symbols: observed local control rates;
curves: calculated local tumor control probabilities (TCP); error bars: 95% CI of TCD50.
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duces hypoxic fraction such as inhibition of mitochon-
drial oxygen consumption [23,30] appears rather less
likely because UT-SCC-5 tumors exhibit very high glyco-
lytic activity in vivo [31-33].
In our previous study pre-treatment with BAY-84-
7296 for two weeks radiosensitized tumors to irradiation
with large single doses resulting in an enhancement ratio
of 1.37 [24], which indicates that the dose to achieve the
same level of local tumor control could be reduced by a
factor of 1.37 if tumors are pre-treated with the inhibi-
tor. This significant radiosensitizing effect could be ex-
plained at least to some extent by the pronounced
reduction of the fraction of radioresistant hypoxic tumor
cells at time of irradiation. These previous findings were
obtained using BAY-84-7296 and prompted us to evalu-
ate here the effect of its derivative BAY-87-2243 on local
tumor control after clinically relevant fractionated irradi-
ation. BAY-87-2243 was chosen due to its higher on-
target activity for further experimental and clinical
evaluation. The lead compound BAY-84-7296 was dis-
covered by a small-molecule library screen for its activity
to suppress HIF-1α protein accumulation under hypoxic
conditions. Subsequent studies on BAY-87-2243 revealed
the mode of action, i.e. inhibition of mitochondrial com-
plex I and reduced hypoxia-induced HIF-1 activity [23].In the present study pre-treatment time with BAY-87-
2243 was reduced to 3 days because we showed that
shorter treatment is sufficient to resolve tumor hypoxia
as detected by pimonidazole hypoxia marker. Pre-
treatment with BAY-87-2243 resulted in an enhance-
ment ratio of 1.23. This effect was less pronounced in
comparison with ER of 1.37 obtained after large single
radiation doses and BAY-84-7296. In addition to longer
pre-treatment time with the compound in single dose
experiment, several biological factors may contribute to
this difference. First, radiation response after single
doses may depend on the hypoxic fraction to a greater
extent than the outcome of fractionated irradiation lead-
ing to a more pronounced radiosensitizing effect in a
single dose setting. Extensive reoxygenation between ra-
diation fractions in UT-SCC-5 [25] may at least in part
explain lower ER. Second, it is well established that in
addition to hypoxia other radiobiological mechanisms
such as repopulation, repair, etc. determine tumor re-
sponse to fractionated irradiation, which can attenuate
the effect of the compound [34].
It has been shown that several other mechanisms can
contribute to the enhanced tumour radiation response
in combination with HIF-1 inhibition. This includes pre-
vention of reconstitution of stromal function after radi-
ation and further sensitization of tumour vessels to
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findings together with the data showing a radioprotective
function of HIF-1α in accumulation of DNA damage re-
sponse proteins [35] led us to hypothesize that application
of BAY-87-2243 during fractionated irradiation in addition
to pre-treatment prior to radiotherapy further improves
local tumor control. Despite of these potential mechanistic
advantages, the latter treatment scheme however, was less
efficacious than pre-treatment with BAY-87-2243 and re-
sulted in an ER of only 1.07. The underlying reasons re-
main unclear. HIF-1α expression in the present study
markedly decreased during BAY-87-2243 treatment prior
to irradiation and it was not tested here whether HIF-1α
recovered thereafter during irradiation to potentiate the
effect of BAY-87-2243. However, we have previously
shown that in UT-SCC-5 tumors despite of extensive re-
oxygenation during fractionated irradiation the levels of
HIF-1α remained unchanged [27] as opposed to HIF-1
up-regulation detected by others in other tumor cell lines
[6,8,16]. Based on these findings, it may be hypothesised
that limited expression of the molecular target during the
course of radiotherapy underlies the lack of further im-
provement of local control. In addition it cannot be ex-
cluded that BAY-87-2243 during irradiation might induce
adverse vascular effects with potentially negative conse-
quences for perfusion and reoxygenation which may have
attenuated the advantageous effect of pre-treatment with
BAY-87-2243. Importantly, our finding that BAY-87-2243
is efficacious when given before but not during or after RT
is in contrast to several other reports [16,17,36]. In the lat-
ter studies which used tumor growth delay as experimen-
tal endpoint, HIF-1 inhibition during and after RT but not
prior to RT was efficacious. Whereas HIF-1 inhibition
during radiotherapy may decrease the growth rate of sur-
viving tumor cells influencing growth delay, it may not in-
duce killing of tumor stem cells to an extent detectable as
improved local tumor control. In addition one may specu-
late that the pharmacological effect of BAY-87-2243 on
mitochondrial production of ROS and subsequent lower
HIF-1 levels may have different radiobiological conse-
quences than other HIF-1 targeting drugs or genetic
knock-down.
Experimental evidence is accumulating that supports
an important role of HIF-1 in chemoresistance by mul-
tiple mechanisms including increased drug efflux and/or
decreased drug uptake, alteration of drug targets, cell
cycle arrest in G1 affecting the cytotoxicity of cell phase-
specific agents, etc. [37]. Deficiencies in nucleotide exci-
sion repair and in mismatch repair negatively affect the
cytotoxicity of DNA interacting agents such as cisplatin
[38]. HIF-1 has been shown in pre-clinical studies to
interfere with these repair systems and it therefore has
been suggested that HIF-1 inhibition can improve the
outcome of radiochemotherapy [14,21,22,39]. In supportof this hypothesis a recent clinical study has revealed a
negative correlation between pre-treatment HIF-1α ex-
pression in head and neck tumors and overall survival
after concomitant cisplatin-based radiochemotherapy
[40]. In line with other pre-clinical and clinical studies,
our results show marginally significant enhancement of
the radiation response by cisplatin [41-44]. BAY-87-2243
administered to tumor-bearing animals before and dur-
ing fractionated cisplatin-based radiochemotherapy did
not improve local tumor control in a single tumor
hSCC. The mechanisms underlying the potential interac-
tions between two different compounds and radiation
and their net effect on local control have not been ad-
dressed in this study and need further investigations.
Classical experiments have been reported that cisplatin
showed greater enhancement in fully hypoxic (clamped)
tumors than in tumors containing both hypoxic and well
oxygenated cells (unclamped) [42]. It can be therefore
speculated that in the present study pronounced reduc-
tion of hypoxic fraction by BAY-87-2243 might at least
in part counteract the effect of cisplatin. It is however
important to take into account considerable intertu-
moral heterogeneity in response to radiochemotherapy
in the present study, which limits the interpretation of
these data. Nevertheless, from a clinical point of view
our results might have important implications for fur-
ther development of this compound in the context of
fractionated radiotherapy. While for radiochemotherapy
it appears that caution and further experiments are
needed, combination of compounds like BAY-87-2243
with radiation alone is of great clinical interest because
many patients are medically unfit for concurrent radio-
chemotherapy. In addition, classical chemotherapy has
substantial side effects and might exhibit only a limited
benefit over radiotherapy alone with regard to local
tumor control.
Conclusion
Pronounced reduction of tumor hypoxia by application
of the novel inhibitor of hypoxia-induced gene activation
BAY-87-2243 before start of fractionated radiotherapy
improved local tumor control. The therapeutic effect of
BAY-87-2243 importantly depended on treatment sched-
ule and was only significant if BAY-87-2243 was admin-
istered prior to fractionated radiotherapy. The data
support the further investigation of such inhibitors for
combination with radiotherapy. In particular further
radiobiological studies are needed to better understand
the interaction of BAY-87-2243 with radiotherapy and
radiochemotherapy which is a prerequisite for the devel-
opment of predictive tests and tools for monitoring.
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